E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
Frank V. Aguirre,Eric J. Topol,James J. Ferguson,Keaven M. Anderson,James C. Blankenship,Richard R. Heuser,Kristina N. Sigmon,Marc Taylor,Ronald S. Gottlieb,Gary Hanovich,Michael A. Rosenberg,Thomas J. Donohue,Harlan F. Weisman,Robert M. Califf +13 more
TL;DR: Bleeding complications unrelated to bypass surgery were two to three times more frequent in patients receiving c7E3 Fab than in those receiving placebo, but most were transient and well tolerated, and risk-factor analysis and modification of concomitant antithrombotic and antiplatelet treatment strategies may aid in reducing bleeding complications and enhancing clinical benefit.
Journal ArticleDOI
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients'data
Salim Yusuf,Christopher B. Granger,John W. Eikelboom,Shamir R. Mehta,J Pogue,P Tait,S Behar,M Benderly,Hanoch Hod,E Kaplinsky,N Barrett,R Bilke,M Luz,M Marhoefer,L Roi,D Trenery,John A. Bittl,H Boersma,Marcus Flather,Colin Baigent,Maarten L. Simoons,Robert M. Califf,Karen S. Pieper,Eric J. Topol,Jeff Weitz,Patrick W. Serruys,Harvey D. White,Karl-Ludwig Neuhaus,Uwe Zeymer,John Simes,P Close,Susan Edwards,P Gallo,M Henis,Sonia S. Anand,W Kimball,C Meanwell,J Villiger,Elliott M. Antman,Eugene Braunwald,Michael F. Gibson,Sean P. Murphy,Lars Grip,Peter Held,Trialist Dti. +44 more
TL;DR: Direct thrombin inhibitors are superior to heparin for the prevention of death or myocardial infarction in patients with acute coronary syndromes, and this information should prompt further clinical development of direct throm bin inhibitors for the management of arterial thrombosis.
Journal ArticleDOI
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the “smoker's paradox” from the GUSTO-I trial, with angiographic insights
Gabriel I. Barbash,Jonathan S. Reiner,Harvey D. White,Robert G. Wilcox,Paul W. Armstrong,Zygmunt Sadowsi,Douglas C. Morris,Philip Aylward,Lynn H. Woodlief,Eric J. Topol,Robert M. Califf,Allan M. Ross +11 more
TL;DR: Smokers receiving thrombolysis for acute myocardial infarction presented 11 years earlier than nonsmokers, which generally accounted for their better outcome, and no significant difference in mortality was seen between smokers and nonsmoker.
Journal ArticleDOI
Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction
Arman T. Askari,Marie Luise Brennan,Xiaorong Zhou,Jeanne K. Drinko,Annitta Morehead,James D. Thomas,Eric J. Topol,Stanley L. Hazen,Marc S. Penn +8 more
TL;DR: A mechanistic link between inflammation and LV remodeling is offered by demonstrating a heretofore unrecognized role for MPO and PAI-1 in orchestrating the myocardial response to AMI.
Journal ArticleDOI
Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the USA: a population-based study.
TL;DR: Fitbit data significantly improved ILI predictions in all five states, with an average increase in Pearson correlation of 0·12 (SD 0·07) over baseline models, corresponding to an improvement of 6·3-32·9%.